Each week, Chemotherapy Advisor offers a briefing on the previous week's oncology articles.
Bevacizumab Plus Chemo Prolongs Survival in
Advanced Cervical Cancer
Patients given bevacizumab survived almost 4 months longer than controls, but had a higher rate of adverse events. Read more
The management of women with advanced or recurrent cervical cancer continues to be a very difficult clinical scenario... Read more
— Don S. Dizon, MD, FACP
Get the CtA app!
Treatment regimens, drug info, and news on the go.
For iOS and Android.
If you were sent this by a colleague and wish to subscribe to Weekly highlights, please click here.
To unsubscribe from the Weekly Highlights click here.
To manage your entire Chemotherapy Advisor profile login to your account.
You are subscribed as: %%EMAIL%%
To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.
All Chemotherapy Advisor newsletters are sent from the domain "email.chemotherapyadvisor.com". When configuring e-mail or spam filter rules, please
use this domain name.
Haymarket Media Inc
114 West 26th St 4th floor
New York, NY 10001